Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The treatment resistant depression market was valued at USD 3496.00 Million in 2025. It is poised to grow at a CAGR of 6.10% during the forecast period of 2026-2035, and reach USD 6320.12 Million by 2035. The market growth is driven by the rising prevalence of refractory depression cases, increasing awareness, advancements in novel therapeutics such as psychedelics and neuromodulation, and growing investments in mental health innovation.
Latest News on the Treatment Resistant Depression Market (2026)
- In April 2026, ATAI Life Sciences and Beckley Psytech reported BPL-003 demonstrated rapid and durable antidepressant response in treatment-resistant depression, advancing psychedelic therapy development programs.
- In March 2026, Johnson & Johnson reported real-world SPRAVATO (esketamine) nasal spray data showing durable antidepressant effects in treatment-resistant depression, confirming sustained long-term clinical benefit.
- In January 2026, Washington University researchers reported an implanted neuromodulation device provided lasting symptom relief in treatment-resistant depression patients, highlighting interventional psychiatric treatment advancements.
Key Market Trends and Insights
- By drug type, NMDA receptor antagonists are likely to dominate in the forecast period, holding approximately 41% revenue share.
- By end user, hospitals are likely to dominate in the forecast period, capturing approximately 44% market share.
- Based on region, the United States is likely to dominate in the forecast period, commanding approximately 47% revenue share.
Market Size and Forecast
- Market Size (2025): USD 3496.00 Million
- Projected Market Size (2035): USD 6320.12 Million
- CAGR (2026-2035): 6.10%
Read more about this report - Request a Free Sample
Treatment Resistant Depression Market Overview
The market is growing steadily due to the rising prevalence of major depressive disorder and unmet treatment needs. Advancements in ketamine-based therapies and neuromodulation techniques are expanding clinical options. Increasing awareness and diagnosis rates are supporting market expansion. However, high costs, limited access, and variable patient response rates continue to restrict broader adoption. The market reached a value of approximately USD 3496.00 Million in 2025.
Treatment Resistant Depression Market Growth Drivers
Real-World Antidepressant Therapies Driving the Market Demand
Rising prevalence of refractory depression cases and the increasing adoption of rapid-acting neuropsychiatric therapies are supporting market expansion. These factors are strengthening demand for advanced treatment pathways and improving long-term clinical outcomes. For instance, in March 2026, Johnson & Johnson reported SPRAVATO (esketamine) real-world data showing durable antidepressant effects in treatment-resistant depression, reinforcing esketamine (Spravato) utilization, and this segment is likely to dominate due to sustained therapeutic effectiveness in the forecast period.
Treatment Resistant Depression Market Trends
Key trends shaping the market include rising adoption of rapid-acting antidepressants, expansion of neuromodulation therapies, and growing integration of precision psychiatry approaches.
Read more about this report - Request a Free Sample
Rising Neuromodulation Innovations Boosting the Market Development
The growing burden of treatment-resistant depression and increasing preference for interventional psychiatric approaches are accelerating the adoption of device-based therapies. These developments are improving treatment response rates and expanding clinical application of brain stimulation technologies. For instance, in January 2026, Washington University researchers reported that an implanted neuromodulation device provided lasting symptom relief in treatment-resistant depression patients, strengthening TMS therapy adoption, and this segment is likely to dominate due to expanding clinical efficacy and procedural advancement.
Treatment Resistant Depression Market Segmentation
Market Breakup by Drug Type
- N-methyl-D-aspartate (NMDA)
- Antidepressants
- Antipsychotics
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
Market Breakup by User
- Hospitals
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Market Breakup by Country
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Read more about this report - Request a Free Sample
Treatment Resistant Depression Market Share
Hospitals Likely to Dominate the Market Segment by End User
Increasing psychiatric admissions, advanced mental health infrastructure, and rising clinical focus on refractory depression cases are supporting steady market expansion. Hospitals are likely to dominate in the forecast period, capturing approximately 44% market share, supported by multidisciplinary care models and integrated treatment pathways, with the esketamine (Spravato) segment likely to dominate due to its rapid-acting antidepressant efficacy in treatment-resistant cases.
Read more about this report - Request a Free Sample
Treatment Resistant Depression Market Analysis by Region
Strong healthcare expenditure, early adoption of novel neuropsychiatric therapies, and high disease burden are driving regional market leadership. The United States is likely to dominate in the forecast period, commanding approximately 47% revenue share, supported by advanced psychiatric care systems and innovation ecosystems, with the ketamine infusion segment likely to dominate due to its widespread clinical utilization in refractory depression management.
Read more about this report - Request a Free Sample
Leading Players in the Treatment Resistant Depression Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Johnson & Johnson (Janssen Pharmaceuticals)
Johnson & Johnson (Janssen Pharmaceuticals), headquartered in New Brunswick, New Jersey, is a key innovator in psychiatric therapeutics. In July 2024, the company submitted an sNDA to the FDA for SPRAVATO® (esketamine) nasal spray for treatment-resistant depression, strengthening esketamine (Spravato) adoption in clinical practice, with this segment likely to dominate due to rapid expansion of fast-acting antidepressant therapies.
AbbVie Inc.
AbbVie Inc., headquartered in North Chicago, Illinois, is a global biopharmaceutical company with a growing neuroscience portfolio. Its research focus includes psychiatric disorders and advanced central nervous system therapies. The company is exploring augmentation strategy approaches to address treatment-resistant depression, supporting pipeline expansion and improving therapeutic response rates across complex depressive disorders in clinical settings.
Eli Lilly and Company
Eli Lilly and Company, headquartered in Indianapolis, Indiana, is a leading pharmaceutical firm with established antidepressant therapies. Its FDA-approved Symbyax® (olanzapine and fluoxetine) is widely used in managing severe depression cases. The company supports TRD management through combination-based treatment approaches, enhancing clinical outcomes in patients unresponsive to standard antidepressant monotherapy options.
Bristol-Myers Squibb
Bristol-Myers Squibb, headquartered in Princeton, New Jersey, is a global biopharmaceutical leader focused on neuroscience innovation. The company is actively advancing pipeline candidates targeting treatment-resistant depression. Its research explores TMS therapy and next-generation neuropsychiatric interventions, aiming to expand treatment options for patients with inadequate response to conventional antidepressant therapies.
Other key players in the market are Otsuka Holdings Co., Ltd., Biogen Inc., Takeda Pharmaceutical Company, Pfizer Inc., Neuronetics, Inc., and Axsome Therapeutics.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the Treatment Resistant Depression Market Report
- What was the treatment resistant depression market value in 2025?
- What is the treatment resistant depression market forecast outlook for 2026-2035?
- What major factors aid the demand for treatment resistant depression market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major treatment resistant depression market trends?
- Which drug type is expected to dominate the market segment?
- Which route of administration is expected to dominate the market segment?
- Which distribution channel is expected to dominate the market segment?
- Which end user is expected to dominate the market segment?
- Who are the key players in the treatment resistant depression market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
